Generic Name and Formulations:
Dexmethylphenidate HCl (single-isomer methylphenidate) 2.5mg, 5mg, 10mg+; tabs; +dye-free.
Novartis Pharmaceuticals Corp
Indications for FOCALIN:
Attention deficit hyperactivity disorder.
Adults and Children:
<6yrs: not established. Individualize. ≥6yrs: initially 2.5mg twice daily. Switching from racemic methylphenidate (eg, Ritalin): ½ of racemic methylphenidate dose. Allow at least 4 hours between doses. May increase by 2.5–5mg weekly; max 20mg/day.
Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family. During or within 14 days of MAOIs.
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. Caution with pressor agents. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), tricyclics (eg, imipramine, clomipramine, desipramine), SSRIs; adjust doses. May decrease effectiveness of antihypertensive agents. Caps: may be affected by drugs that affect pH (eg, antacids, acid suppressants). Risk of serotonin syndrome with serotonergic drugs.
Dyspepsia, dry mouth, decreased appetite, headache, anxiety, anorexia, insomnia, nausea, abdominal pain, weight loss; hypertension, tachycardia, visual disturbances, priapism.
XR 5mg, 10mg, 15mg, 20mg, 30mg, 40mg (YES); 25mg, 35mg (NO); tabs (YES)
XR caps, tabs—100
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- Daily Alcohol Use May Drive Chronic Pain in Adults With HIV
- Tools to Address the Opioid Crisis
- AHA/ACC Release Updated Guidelines for Cholesterol Management
- Women Fed Soy Formula as Infants More Likely to Experience Menstrual Pain